Vimarsana
Biggest News Aggregation in the World

Page 16 - Michael Yu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Yu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Yu Today - Breaking & Trending Today

When your faith makes you an enemy of the state - Vimarsana News

When your faith makes you an enemy of the state

It was July 20, 1999. Michael Yu, an accountant and Falun Gong practitioner remembers what happened in China well. Then Chinese President Jiang Zemin had declared millions of Yu’s fellow Falun Gong practitioners a threat to the government. A warrant was also issued for the arrest of Li Hongzhi who had founded the spiritual movement only seven years earlier in 1992.

What Default? With Confetti and Fanfare, Evergrande Says It's Ready to Build. - Vimarsana News

What Default? With Confetti and Fanfare, Evergrande Says It's Ready to Build.

Weeks after signaling it could no longer go on, the troubled Chinese property developer has pledged to start paying its workers and completing projects again. Buyers are skeptical.

Pharmacy of the world: China's quest to be the No. 1 drugmaker - Vimarsana News

Pharmacy of the world: China's quest to be the No. 1 drugmaker

China’s pharmaceutical sector, long known for generic drugs and raw materials, is rapidly emerging as a force in innovative medicines. This dovetails with Beijing’s ambition to surpass the U.S. industry, especially in biologics. China’s methods, however, have drawn significant criticism.

Source: nikkei.com
Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications - Vimarsana News

Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia - Vimarsana News

Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...